A phase III registration study of Nelotanserin in Lewy Body Dementia (LBD) patients.
Latest Information Update: 28 Sep 2021
At a glance
- Drugs Nelotanserin (Primary)
- Indications Dementia; Lewy body disease
- Focus Registrational; Therapeutic Use
- Sponsors Sio Gene Therapies [CEASED]
- 15 Feb 2017 New trial record
- 13 Feb 2017 According to Axovant Sciences media release, company plans to begin this study in second half of 2017